Prelude Therapeutics Incorporated (PRLD)

Market Cap	55.04M
Revenue (ttm)	3.00M
Net Income (ttm)	-131.52M
Shares Out	55.04M
EPS (ttm)	-1.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,023
Open	1.040
Previous Close	1.050
Day's Range	0.989 - 1.060
52-Week Range	0.931 - 6.800
Beta	1.48
Analysts	Buy
Price Target	5.33 (+433.0%)
Earnings Date	Nov 6, 2024

About PRLD

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 128
• Stock Exchange: NASDAQ
• Ticker Symbol: PRLD
• Website: https://preludetx.com

Analyst Forecast

According to 3 analysts, the average rating for PRLD stock is "Buy." The 12-month stock price forecast is $5.33, which is an increase of 433.00% from the latest price.

Price Target

$5.33

(433.00% upside)

Analyst Consensus: Buy